Xuanjing Biotech completed a Pre-A round of financing exceeding 200 million yuan.

36Kr learned that on March 20th, "Xuanjing Biotech", a clinical-stage small nucleic acid drug company, announced the completion of a Pre-Series A financing round exceeding RMB 200 million, led by Kangjun Capital. Delian Capital, Huatai Genscript Fund, Jinyifu New, Guohai Innovation Capital, Legend Capital, and existing shareholder Yuanxi Haihe jointly participated in this round of investment.